Medincell Sa Stock Z Score
| MDCLF Stock | USD 34.39 0.00 0.00% |
What is Altman Z-Score?
The Altman Z-Score is one of the most widely-used financial formulas to predict bankruptcy risk. Developed by Edward Altman in 1968, this model combines five key financial ratios to generate a single score that indicates the likelihood of financial distress within two years.
How to Interpret MedinCell Z-Score
Z-Score above 3.0: Safe zone - Low bankruptcy risk
Z-Score 2.7 - 3.0: Gray zone - Moderate risk
Z-Score 1.8 - 2.7: Warning zone - Elevated risk
Z-Score below 1.8: Distress zone - High bankruptcy risk
Why MedinCell Z-Score Matters
Investors use the Z-Score to assess financial health before making investment decisions. A declining Z-Score over time may signal deteriorating fundamentals, while an improving score suggests strengthening financial position. The model evaluates five critical metrics: working capital to assets, retained earnings to assets, EBIT to assets, market value of equity to total liabilities, and sales to assets.
MedinCell Z-Score Analysis
The module uses available fundamental data of MedinCell to calculate the Altman Z score based on five fundamental metrics from the company's most recent public disclosure documents. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MedinCell SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
MedinCell |
MedinCell 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to MedinCell's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of MedinCell.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in MedinCell on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding MedinCell SA or generate 0.0% return on investment in MedinCell over 90 days. MedinCell is related to or competes with BioInvent International, Avacta Group, Healios KK, PureTech Health, GenSight Biologics, Northwest Biotherapeutics, and Verano Holdings. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers an... More
MedinCell Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure MedinCell's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess MedinCell SA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1273 | |||
| Maximum Drawdown | 392.69 |
MedinCell Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for MedinCell's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as MedinCell's standard deviation. In reality, there are many statistical measures that can use MedinCell historical prices to predict the future MedinCell's volatility.| Risk Adjusted Performance | 0.1139 | |||
| Jensen Alpha | 6.47 | |||
| Total Risk Alpha | 1.52 | |||
| Treynor Ratio | 7.96 |
MedinCell February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1139 | |||
| Market Risk Adjusted Performance | 7.97 | |||
| Mean Deviation | 12.87 | |||
| Coefficient Of Variation | 774.6 | |||
| Standard Deviation | 50.7 | |||
| Variance | 2570.14 | |||
| Information Ratio | 0.1273 | |||
| Jensen Alpha | 6.47 | |||
| Total Risk Alpha | 1.52 | |||
| Treynor Ratio | 7.96 | |||
| Maximum Drawdown | 392.69 | |||
| Skewness | 7.75 | |||
| Kurtosis | 60.0 |
MedinCell SA Backtested Returns
MedinCell is out of control given 3 months investment horizon. MedinCell SA has Sharpe Ratio of 0.13, which conveys that the firm had a 0.13 % return per unit of risk over the last 3 months. We were able to break down and interpolate sixteen different technical indicators, which can help you to evaluate if expected returns of 6.54% are justified by taking the suggested risk. Use MedinCell SA Risk Adjusted Performance of 0.1139, mean deviation of 12.87, and Standard Deviation of 50.7 to evaluate company specific risk that cannot be diversified away. MedinCell holds a performance score of 10 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 0.82, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, MedinCell's returns are expected to increase less than the market. However, during the bear market, the loss of holding MedinCell is expected to be smaller as well. Use MedinCell SA variance, as well as the relationship between the maximum drawdown and rate of daily change , to analyze future returns on MedinCell SA.
Auto-correlation | 0.00 |
No correlation between past and present
MedinCell SA has no correlation between past and present. Overlapping area represents the amount of predictability between MedinCell time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of MedinCell SA price movement. The serial correlation of 0.0 indicates that just 0.0% of current MedinCell price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 172.0 |
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
Based on the company's disclosures, MedinCell SA has a Z Score of 9.0. This is 33.33% higher than that of the Healthcare sector and 169.46% higher than that of the Biotechnology industry. The z score for all United States stocks is 3.21% lower than that of the firm.
MedinCell Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MedinCell's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of MedinCell could also be used in its relative valuation, which is a method of valuing MedinCell by comparing valuation metrics of similar companies.MedinCell is currently under evaluation in z score category among its peers.
MedinCell Fundamentals
| Return On Asset | -0.4 | |||
| Operating Margin | (3.25) % | |||
| Current Valuation | 190.33 M | |||
| Shares Outstanding | 25.22 M | |||
| Shares Owned By Insiders | 47.61 % | |||
| Shares Owned By Institutions | 19.00 % | |||
| Price To Book | 34.52 X | |||
| Price To Sales | 31.58 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 4.09 M | |||
| EBITDA | (21.45 M) | |||
| Net Income | (24.81 M) | |||
| Cash And Equivalents | 34.39 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 16.25 M | |||
| Debt To Equity | 4.86 % | |||
| Current Ratio | 2.84 X | |||
| Book Value Per Share | (1.04) X | |||
| Cash Flow From Operations | (21.36 M) | |||
| Earnings Per Share | (0.88) X | |||
| Number Of Employees | 151 | |||
| Beta | 1.02 | |||
| Market Capitalization | 244.65 M | |||
| Total Asset | 44.3 M | |||
| Z Score | 9.0 | |||
| Net Asset | 44.3 M |
About MedinCell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MedinCell SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedinCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedinCell SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in MedinCell Pink Sheet
MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.